Trial of Oral Versus Intravenous Proton Pump Inhibitor on Intragastric pH in Patients With Bleeding Ulcers
Not Applicable
Completed
- Conditions
- Peptic Ulcer Hemorrhage
- Interventions
- Drug: Proton pump inhibitor (lansoprazole)
- Registration Number
- NCT00573924
- Lead Sponsor
- University of Southern California
- Brief Summary
Patients with bleeding ulcers identified by endoscopy will be randomly assigned to receive an acid-blocking drug (called a proton pump inhibitor \[PPI\]) either by mouth every 3 hours for 24 hours or intravenously (IV) by constant infusion for 24 hours. A pH probe in the stomach will be used to determine intragastric pH (a measure of the acid production in the stomach) at baseline and during the 24 hours of therapy. The purpose of the study is to determine if the continuous intravenous administration of the drug provides better reduction of acid in the stomach than the oral administration.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 66
Inclusion Criteria
- Patients presenting to hospital with overt upper GI bleeding and found to have an ulcer as the cause on endoscopy
Exclusion Criteria
- Previous gastric surgery
- Active bleeding at end of endoscopy (despite hemostatic therapy)
- Recent PPI or H2RA use
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Proton pump inhibitor (lansoprazole) Oral PPI 2 Proton pump inhibitor (lansoprazole) Intravenous PPI
- Primary Outcome Measures
Name Time Method Intragastric pH > 6 24 hours
- Secondary Outcome Measures
Name Time Method Mean intragastric pH 24 hrs
Trial Locations
- Locations (1)
L.A. County + U.S.C. Medical Center
🇺🇸Los Angeles, California, United States